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Abstract
Background: Bowel cancer is common and is a major cause of death. Most people with bowel
symptoms who meet the criteria for urgent referral to secondary care will not be found to have
bowel cancer, and some people who are found to have cancer will have been referred routinely
rather than urgently. If general practitioners could better identify people who were likely to have
bowel cancer or conditions that may lead to bowel cancer, the pressure on hospital clinics may be
reduced, enabling these patients to be seen more quickly. Increased levels of an enzyme called
matrix metalloproteinase 9 (MMP-9) have been found to be associated with such conditions, and
this can be measured from a blood sample. This study aims to find out whether measuring MMP-9
levels could improve the appropriateness of urgent referrals for patients with bowel symptoms.
Methods: People aged 18 years or older referred to a colorectal clinic will be asked to complete
a questionnaire about symptoms, recent injuries or chronic illnesses (these can increase the level
of matrix metalloproteinases) and family history of bowel cancer. A blood sample will be taken
from people who consent to take part to assess MMP-9 levels, and the results of examination at
the clinic and/or investigations arising from the clinic visit will be collected from hospital records.
The accuracy of MMP-9 will be assessed by comparing the MMP-9 level with the resulting diagnosis.
The combination of factors (e.g. symptoms and MMP-9 level) that best predict a diagnosis of
malignancy (invasive disease or polyps) will be determined.
Discussion: Although guidelines are in place to facilitate referrals to colorectal clinics, symptoms
alone do not adequately distinguish people with malignancy from people with benign conditions.
This study will establish whether MMP-9 could assist this process. If this were the case,
measurement of MMP-9 levels could be used by general practitioners to assist in the identification
of people who were most likely to have bowel cancer or conditions that may lead to bowel cancer,
and who should, therefore, be referred most urgently to secondary care.
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Background
Bowel cancer is common and is a major cause of death. It
is the third and second most common cancer in men and
women, respectively, in England, and there are over
28000 new cases in England, and over 14000 deaths in
England and Wales each year.[1,2] Survival is associated
with stage of disease at diagnosis.[3] Benefits, in terms of
improved survival, improved quality of life and reduced
treatment costs, could be accrued by earlier diagnosis. It is,
therefore, important to concentrate on improving early
detection of disease.
Guidelines have been introduced to facilitate appropriate
primary care referrals for people with suspected can-
cer.[4,5] Most people with bowel symptoms who meet the
criteria for urgent referral will not, however, be found to
have bowel cancer.[6] Also, some people who are subse-
quently found to have cancer will have been referred rou-
tinely rather than urgently. If people who were most likely
to have bowel cancer or conditions that may lead to bowel
cancer could be identified and referred most urgently, the
pressure on hospital clinics could be reduced, enabling
these patients to be seen more quickly.
Available diagnostic tests for bowel cancer include colon-
oscopy and flexible sigmoidoscopy. These tests are inva-
sive with an element of risk, and they usually need to be
done in hospital. A simple and acceptable test that could
be used by general practitioners could save many people
from having unnecessary and invasive procedures.
Increased levels of an enzyme called matrix metalloprotei-
nase 9 (MMP-9) have been found to be associated with
bowel cancer and conditions that may lead to bowel can-
cer,[7-9] and this can be measured from a blood sample.
Study aim
To find out whether a new blood test (MMP-9) could
improve the appropriateness of urgent referrals for
patients with bowel symptoms.
Study objectives
To describe quality of life, symptom profiles and anxiety
in new referrals to colorectal clinics. To take a blood sam-
ple from each person to measure their MMP-9 level. To
review each person's hospital records to find out if they
were diagnosed with bowel cancer or polyps. To deter-
mine the combination of factors (e.g. symptoms and
MMP-9 level) that best predict whether a person has
bowel cancer or is at high risk of developing the disease.
Methods
Study design
Evaluation of the accuracy of a diagnostic test: accuracy of
MMP9 will be assessed by comparison with the results of
examinations and investigations undertaken at, or
prompted by, the colorectal clinic visit.
Population to be studied
People will be eligible if they are aged 18 years or older
and are a new referral (routine or urgent) to the colorectal
clinic at University Hospital Birmingham NHS Founda-
tion Trust during the study period.
Selection of participants
Potential participants will be identified using the Trust
appointment system. An information leaflet, cover letter
and questionnaire will be sent to each eligible person
approximately two weeks before their clinic appointment.
The questionnaire asks about symptoms, recent injuries or
chronic illnesses (as these can also increase the level of
matrix metalloproteinases) and whether the respondent
or any close family members have had bowel cancer. Peo-
ple who may want to take part will be asked to come to the
clinic at their appointment time with the completed ques-
tionnaire. The study receptionist will ask potential partic-
ipants as they arrive at the clinic whether they would like
to speak with a researcher about the study. Those consid-
ering participation will be asked to complete two short
survey instruments as they wait: the SF-12 assesses overall
health status[10] and the State-Trait Anxiety Inventory
assesses temporary and long-term anxiety [11].
To ensure that people who attend the clinic at short notice
also have the opportunity to participate, we will put a
poster in the waiting room of the clinic. The poster will
outline in layman's terms the aim of the study and what
taking part would entail and ask that patients tell the
study receptionist if they are interested in participating.
Interested patients will be asked to read the information
leaflet and, if they still wish to participate, to complete the
questionnaires.
Informed consent
A trained researcher will speak with each potential partic-
ipant and seek informed consent. Private rooms at the
colorectal clinic will be available for this purpose. Work-
ing to a script to avoid interviewer bias and ensure that all
important points are covered, the researcher will outline
why the study is being done, what taking part would
mean, and the associated risks. Potential participants will
be able to ask questions at any point. People who are una-
ble to understand why the study is being done or what
taking part would mean will be excluded. People who
have not been excluded and who decide that they would
like to take part in the study will be asked to sign the con-
sent form. The survey instruments and questionnaire will
be collected from consented participants and checked.
Non-directive assistance will be provided for any unan-
swered questions.BMC Cancer 2006, 6:251 http://www.biomedcentral.com/1471-2407/6/251
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Exclusion criteria
People who are unwilling to give informed consent or
who are unable to understand why the study is being done
or what taking part would mean will be excluded.
Clinical evaluations, laboratory tests and follow-up
The researcher will take a blood sample for MMP-9 esti-
mation from consented participants. Each person will
then be taken back into the waiting room for their clinic
appointment. At the end of each session, all blood sam-
ples will be taken to the Institute of Cancer Studies at the
University of Birmingham, where they will be analysed.
To reduce bias, the technician doing the analysis will not
be aware of the participants' symptoms or diagnoses.
The results of each participant's examination at the color-
ectal clinic and any investigations arising from the clinic
visit will be collected from their hospital records using a
standard proforma. This will be done after a gap of at least
two months to allow relevant investigations to be com-
pleted and documented. Any missing information will be
sought from the consultant who cared for the person. Par-
ticipants without a diagnosis of colorectal cancer will be
flagged and followed-up via the NHS Central Register.
Procedures for handling data
All data will be entered onto password-protected data-
bases. Passwords will be changed regularly and only
known by core research staff. Personal data will be stored
in a separate database with a different password from
other data. Participants will also be allocated a unique
study number that will be used when possible, and the
results of the study will only be presented so that no single
person can be identified. Members of the research team
from the University will hold honorary contracts with the
Trust, and all members of the research team are trained in
procedures related to confidentiality.
Sample size estimate
The sensitivity of a diagnostic test is important when a dis-
ease has serious consequences, for example colorectal
neoplasia. We have, therefore, based our calculation on
the confidence interval and precision with which we want
to estimate the sensitivity of MMP-9. We obtained a sensi-
tivity of 99% in a pilot study of 46 normal volunteers and
300 patients attending a specialist clinic. To estimate this
sensitivity with +/-2.5% precision and a 95% confidence
interval, we need blood samples from 60 people with
colorectal neoplasia. Based on studies where asympto-
matic populations were screened,[12-14] we conserva-
tively estimate the prevalence of colorectal neoplasia as
6%. Using this prevalence, the overall sample size would
be 60 × 100/6 = 1000 people, and 940 people would not
have colorectal neoplasia. This would allow us to estimate
a specificity of 63% (as obtained in the pilot study) with
+/-4.0% precision and a 95% confidence interval. This
precision can be improved to +/-3.0% by increasing the
number of people without colorectal neoplasia to 994.
The overall sample size would then be (994 × 100/94 =)
1057 people, and we estimate that it will take about 60
weeks to complete recruitment (figure 1). We would
expect (1057 - 994 =) 63 of these people to have colorectal
neoplasia, which would still allow us to estimate a sensi-
tivity of 99% with +/-2.5% precision and a 95% confi-
dence interval.
Analysis
Accuracy of MMP-9
ROC curve analyses will be undertaken to permit deci-
sions regarding the best choice of cut-off points (MMP-9)
to achieve specified levels of misclassification (either over-
all misclassification or maximum negative predictive
value). Supplementary analyses of appropriate subgroups
(initially by logistic linear regression) will determine
whether different cut-offs are appropriate in different age
groups or, for example, symptom profiles. The sensitivity,
specificity, positive predictive value and negative predic-
tive value of the test will be calculated. Confidence inter-
vals will be provided for all summary statistics.
Predicting those patients who will have a diagnosis of cancer
The purpose of the analysis is to determine whether the
routine estimation of MMP-9 would better enable identi-
fication of those patients with significant pathology. Inde-
pendent variables will include age, sex, socio-economic
status, symptoms, whether close family members have
had bowel cancer, and MMP-9 level. Given the categorical
nature of the outcome (no disease, polyps, invasive dis-
ease), discriminant analysis will be used to determine the
combination of factors that best predicts a diagnosis of
malignancy (invasive disease/polyps).
Research governance
The dignity, rights, safety and well being of participants
will be given priority at all times. All relevant agencies will
be made fully aware of the research and all relevant pro-
fessionals will be asked to take responsibility for clinical
care. Adverse event monitoring will be undertaken. The
chief and key investigators will form a trial management
group, which will meet regularly to review the conduct of
the research and fidelity to the trial protocol, including
uptake and progress towards the recruitment target. The
researchers will record reasons for exclusion and any nota-
ble events. They will meet regularly to review these practi-
cal issues, and a representative will report back at the trial
management group meeting.BMC Cancer 2006, 6:251 http://www.biomedcentral.com/1471-2407/6/251
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Ethical approval
This study has been approved by North Birmingham
Local Research Ethics Committee: reference 04/Q2704/
29.
Discussion
Bowel cancer is common and is a major cause of death.
Although guidelines are in place to facilitate referrals to
colorectal clinics, symptoms alone may not adequately
distinguish people with malignancy from people with
benign conditions. If general practitioners could identify
people who were most likely to have bowel cancer or con-
ditions that may lead to bowel cancer, the pressure on
hospital clinics could be reduced, enabling these patients
to be seen more quickly. A blood test is likely to be accept-
able to most people. Increased levels of an enzyme called
matrix metalloproteinase 9 (MMP-9) have been found to
be associated with bowel cancer and conditions that may
lead to bowel cancer, and this can be measured from a
blood sample. This study will establish whether measure-
ment of MMP-9 levels from a blood sample could
improve the appropriateness of urgent referrals for
patients with bowel symptoms.
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Research plan and study design Figure 1
Research plan and study design.
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